Basic Information
Rolufta Ellipta (previously Rolufta)
Regulatory Information
EMEA/H/C/004654
March 20, 2017
January 26, 2017
14
March 28, 2025
Company Information
Ireland
12 Riverwalk Citywest Business Campus Dublin 24 D24 YK11
GLAXOSMITHKLINE TRADING SERVICES LIMITED
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Overview Summary
Rolufta Ellipta is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Rolufta Ellipta is used for maintenance (regular) treatment. Rolufta Ellipta contains the active substance umeclidinium bromide.